Want to see HK:2197 full AI Analyst Report?
2197 Stock Chart & Stats
HK$2.37
>-HK$0.01(-2.10%)
At close: 4:00 PM EST
HK$2.37
>-HK$0.01(-2.10%)
Day’s Range― - ―
52-Week RangeHK$0.37 - HK$3.20
Previous CloseN/A
Volume1.38M
Average Volume (3M)29.82M
Market Cap
HK$1.91B
Enterprise ValueHK$2.58K
Total Cash (Recent Filing)HK$286.15M
Total Debt (Recent Filing)HK$10.62M
Price to Earnings (P/E)―
Beta2.47
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding1,298,413,100
10 Day Avg. Volume32,349,599
30 Day Avg. Volume29,824,166
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)-1.47
Price to Sales (P/S)775.86
P/FCF Ratio-13.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary PlatformThe proprietary trimer-tag technology is a durable competitive asset that can be applied across multiple vaccine candidates. Platform ownership supports repeatable R&D workflows, potential licensing or partnerships, and long-term value creation independent of any single product's short-term sales performance.
Integrated Vaccine CapabilitiesVertical integration across R&D, manufacturing and commercialization increases control over product quality, time-to-market and margins for approved vaccines. Sustained manufacturing capability is a structural advantage that enables contract manufacturing or scale-up if pipeline candidates reach approval.
Product Development Track RecordHaving advanced vaccine candidates and a COVID-19 program demonstrates regulatory, clinical and commercial execution experience. That institutional know-how and data generation capabilities are durable assets for developing next-generation or variant-targeted vaccines and for attracting collaborators.
Bears Say
Severe Revenue DeclineA ~93% revenue collapse is a structural red flag: it erodes operating scale, undermines commercial footholds and reduces available resources for R&D and manufacturing. Sustained revenue loss weakens bargaining power with partners and suppliers and impairs long-term ability to execute the clinical pipeline.
Negative Shareholder EquityPersistent negative equity signals accumulated deficits that limit financial flexibility. It raises refinancing risk, increases sensitivity to funding availability, and constrains strategic options like M&A or large-scale manufacturing investments, making long-term scale-up and sustained operations harder without external capital.
Chronic Cash BurnConsistent negative operating and free cash flow indicates ongoing reliance on external funding or asset sales. Chronic cash burn threatens continuity of R&D, regulatory submissions and commercial activities, and increases dilution or financing costs, undermining the company's ability to realize platform value over time.
Clover Biopharmaceuticals Ltd. News
2197 FAQ
What was Clover Biopharmaceuticals Ltd.’s price range in the past 12 months?
Clover Biopharmaceuticals Ltd. lowest stock price was HK$0.36 and its highest was HK$3.20 in the past 12 months.
What is Clover Biopharmaceuticals Ltd.’s market cap?
Clover Biopharmaceuticals Ltd.’s market cap is HK$1.91B.
When is Clover Biopharmaceuticals Ltd.’s upcoming earnings report date?
Clover Biopharmaceuticals Ltd.’s upcoming earnings report date is Aug 26, 2026 which is in 40 days.
How were Clover Biopharmaceuticals Ltd.’s earnings last quarter?
Clover Biopharmaceuticals Ltd. released its earnings results on Mar 25, 2026. The company reported -HK$0.092 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Clover Biopharmaceuticals Ltd. overvalued?
According to Wall Street analysts Clover Biopharmaceuticals Ltd.’s price is currently Overvalued.
Does Clover Biopharmaceuticals Ltd. pay dividends?
Clover Biopharmaceuticals Ltd. does not currently pay dividends.
What is Clover Biopharmaceuticals Ltd.’s EPS estimate?
Clover Biopharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Clover Biopharmaceuticals Ltd. have?
Clover Biopharmaceuticals Ltd. has 1,298,413,100 shares outstanding.
What happened to Clover Biopharmaceuticals Ltd.’s price movement after its last earnings report?
Clover Biopharmaceuticals Ltd. reported an EPS of -HK$0.092 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.563%.
Which hedge fund is a major shareholder of Clover Biopharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in HK:2197
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Clover Biopharmaceuticals Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
589.23%
12-Months-Change
Fundamentals
Return on Equity
11.40%
Trailing 12-Months
Asset Growth
-41.03%
Trailing 12-Months
Company Description
Clover Biopharmaceuticals Ltd.
Clover Biopharmaceuticals, Ltd. is a biotechnology enterprise focused on discovering, developing, and commercializing innovative vaccines and biological therapies. Their efforts target infectious diseases, various cancers, and autoimmune conditions. The company's pipeline features several key candidates: SCB-2019 (CpG 1018/Alum): A COVID-19 vaccine candidate currently advancing through Phase II/III clinical trials. SCB-313: A trimeric fusion protein aimed at treating severe intracavitary malignancies, including malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis, addressing a significant global medical need. SCB-808: Undergoing pivotal Phase III clinical trials for the management of rheumatic disorders. SCB-420: An aflibercept biosimilar in preclinical development for ophthalmologic conditions like wet age-related macular degeneration. SCB-219: A novel TPOR agonist in preclinical stages for the treatment of chemotherapy-induced thrombocytopenia and immune thrombocytopenic purpura. Clover also holds a collaboration and supply agreement with Dynavax, which provides its CpG 1018 adjuvant for use in preclinical studies. The company was established in 2007 and is based in Shanghai, China.
Technical Analysis
Brii Biosciences Limited
―
Genor Biopharma Holdings Limited
―
Jiangsu Recbio Technology Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―
AIM Vaccine Co., Ltd. Class H
―